Literature DB >> 33107987

Prognostic Impact of Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma Patients.

Duo Zhang1,2, Di Tang1,2, Yu Heng1,2, Xiao-Ke Zhu1,2, Liang Zhou1,2, Lei Tao1,2, Li-Ming Lu3.   

Abstract

OBJECTIVES/HYPOTHESIS: Tumor-infiltrating lymphocytes (TILs) has been shown to be associated with the prognosis of many tumors, yet few studies have investigated their roles in laryngeal squamous cell carcinoma (LSCC). We aim to investigate the prognostic values of tumor-infiltrating CD3+ /CD4+ /CD8+ /Foxp3+ T-cells and neutrophils in LSCC patients that received total or partial laryngectomy. STUDY
DESIGN: Retrospective case series of LSCC patients who underwent total or partial laryngectomy from 2013 to 2014 at Eye, Ear, Nose, and Throat Hospital of Fudan University.
METHODS: In our study, 41 tumor tissues from patients with LSCC were retrospectively assessed using immunohistochemistry for CD3+ /CD4+ /CD8+ /Foxp3+ T-cells and CD66b+ neutrophils. Overall survival (OS) and disease-free survival (DFS) were recorded using Kaplan-Meier methods.
RESULTS: Generally, patients with high density of TILs (CD3, CD4, CD8) showed improved OS or DFS. Specifically, high density of CD3+ TILs were associated with better OS, yet poorer OS and DFS for CD66b+ neutrophils. Patients with an Immunoscore of 0-1 experienced the worst OS and DFS, compared with Immunoscore 2-4 (P = .0111 for OS, P = .0391 for DFS). In Cox proportional hazards analysis adjusted for N stage and T stage, only stroma CD66b+ neutrophils densities were able to predict OS, with odds ratios of 4.819 (95% confidence interval [CI] 1.149-20.206; P = .032*), and DFS 2.888 (95% CI 1.043-7.997; P = .041*).
CONCLUSIONS: The density of TILs and CD66b+ neutrophils may help predict the prognosis of patients with LSCC after surgery. LEVEL OF EVIDENCE: 3 Laryngoscope, 131:E1249-E1255, 2021.
© 2020 American Laryngological, Rhinological and Otological Society Inc, "The Triological Society" and American Laryngological Association (ALA).

Entities:  

Keywords:  CD3; CD66b; CD8; Tumor-infiltrating lymphocytes; laryngeal squamous cell carcinoma

Mesh:

Year:  2020        PMID: 33107987     DOI: 10.1002/lary.29196

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  6 in total

1.  Neutrophils Promote Larynx Squamous Cell Carcinoma Progression via Activating the IL-17/JAK/STAT3 Pathway.

Authors:  Tianyi Liu; Shimin Zong; Yang Jiang; Rui Zhao; Jie Wang; Qingquan Hua
Journal:  J Immunol Res       Date:  2021-12-13       Impact factor: 4.818

Review 2.  Tumor-Infiltrating Lymphocytes in the Tumor Microenvironment of Laryngeal Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.

Authors:  Juan P Rodrigo; Mario Sánchez-Canteli; Fernando López; Gregory T Wolf; Juan C Hernández-Prera; Michelle D Williams; Stefan M Willems; Alessandro Franchi; Andrés Coca-Pelaz; Alfio Ferlito
Journal:  Biomedicines       Date:  2021-04-28

3.  Tumor-Infiltrating PD-L1+ Neutrophils Induced by GM-CSF Suppress T Cell Function in Laryngeal Squamous Cell Carcinoma and Predict Unfavorable Prognosis.

Authors:  Di Tang; Duo Zhang; Yu Heng; Xiao-Ke Zhu; Han-Qing Lin; Jian Zhou; Lei Tao; Li-Ming Lu
Journal:  J Inflamm Res       Date:  2022-02-16

4.  T-Cell Heterogeneity in Baseline Tumor Samples: Implications for Early Clinical Trial Design and Analysis.

Authors:  Laura Brennan; Jurriaan Brouwer-Visser; Eveline Nüesch; Maria Karpova; Astrid Heller; Fabien Gaire; Meike Schneider; Bruno Gomes; Konstanty Korski
Journal:  Front Immunol       Date:  2022-04-27       Impact factor: 8.786

5.  Immune Cell and Biochemical Biomarkers in Advanced Laryngeal Cancer.

Authors:  Ana Jotic; Jovica Milovanovic; Katarina Savic-Vujovic; Zorana Radin; Branislava Medic; Miljan Folic; Bojan Pavlovic; Aleksandar Vujovic; Dusko Dundjerovic
Journal:  Dose Response       Date:  2022-07-19       Impact factor: 2.623

Review 6.  Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: Ready for Prime Time?

Authors:  Alhadi Almangush; Stijn De Keukeleire; Sylvie Rottey; Liesbeth Ferdinande; Tijl Vermassen; Ilmo Leivo; Antti A Mäkitie
Journal:  Cancers (Basel)       Date:  2022-03-18       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.